Last reviewed · How we verify
NCT04268641: POSIT-HEMI
Evaluation of Positioning Protocols on a Wheelchair in Hemiplegic Patients
NA trial testing Arm 1 in Hemiplegia And/or Hemiparesis Following Stroke in 24 participants. Completed in 11 December 2023.
11 December 2023
Quick facts
| Lead sponsor | Hôpital NOVO |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 24 |
| Start date | 28 August 2020 |
| Primary completion | 11 December 2023 |
| Estimated completion | 11 December 2023 |
| Sites | 7 locations across France |
Drugs / interventions tested
- Arm 1
- Arm 2
- Arm 3
- Arm 4
- Arm 5
- Arm 6
Conditions studied
- Hemiplegia And/or Hemiparesis Following Stroke — all drugs for Hemiplegia And/or Hemiparesis Following Stroke →
Sponsor
Hôpital NOVO — full company profile →
Who can join
18 and older, any sex, with Hemiplegia And/or Hemiparesis Following Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this study is to assess the interest of using wheelchair positioning equipment on the decrease of postural disorders, compared to the standard use of a wheelchair
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04268641
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Arm 1
Trials testing the same drug.
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT06880991 — Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis · recruiting
- NCT06620796 — A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT05517135 — tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrel · recruiting
- NCT05556070 — Brighter Bites & UT Physicians Produce Rx Program · NA · completed
Other Hôpital NOVO trials
Trials by the same sponsor.
- NCT07394478 — Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rheumatica · not yet recruiting
- NCT07412340 — Disarticulation Septoplasty Versus Classical Way · not yet recruiting
- NCT07298070 — Functional and Aesthetic Outcomes Following Lower Lip Reconstruction · not yet recruiting
- NCT07257094 — Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Reha · recruiting
- NCT07505706 — Patient Journey in Palliative Care Within the NOVO Hospital Group. · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04268641 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hôpital NOVO
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04268641.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing